Versican Plus L4 Suspension for Injection for Dogs

Dogs:
Common
(1 to 10 animals / 100 animals treated):
injection site swelling
Rare
(1 to 10 animals / 10,000 animals
treated):
hypersensitivity reaction
(anaphylaxis,
angioedema, circulatory shock,
collapse, diarrhoea, dyspnoea,
vomiting)
anorexia, decreased activity
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
hyperthermia, lethargy, malaise
immune mediated haemolytic anaemia,
immune mediated haemolytic
thrombocytopenia, immune mediated
polyarthritis
A transient swelling (up to 5 cm) which can be painful, warm or reddened. Any such
swelling will either have spontaneously resolved or be greatly diminished by 14 days
after vaccination.
If a hypersensitivity reaction occurs, appropriate treatment should be administered
without delay. Such reactions may evolve to a more severe condition which may be
life-threatening.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See also section16 of the
package leaflet for contact details.